Sotera Health Co — fact timeline

Sotera Health Co shareholders approved Ratification of Ernst & Young LLP as the independent registered public accounting firm for fiscal year 2026 at the 2026-05-21 meeting.

“Ratification of the Appointment of the Company’s Independent Registered Public Accounting Firm For Against Abstain Broker Non-Votes 267,310,915 223,069 55,857 N/A”

Sotera Health Co shareholders approved Advisory approval of the compensation of the Company’s named executive officers at the 2026-05-21 meeting.

“Approval, on an Advisory Basis, of the Compensation of the Company’s Named Executive Officers For Against Abstain Broker Non-Votes 257,678,396 6,586,053 51,797 3,273,595”

Sotera Health Co shareholders approved Election of all four Class III director nominees at the 2026-05-21 meeting.

“Sotera Health Company (the “Company”) held its 2026 annual meeting of stockholders on May 21, 2026 (the “Annual Meeting”). At the Annual Meeting, the stockholders (1) elected all four director nominees as Class III directors to serve a three-year term until the 2029 annual meeting of stockholders and until their successors are duly elected and qualified”

Sotera Health Co entered into Amendment No. 7 to the First Lien Credit Agreement with JPMorgan Chase Bank, N.A. valued at aggregate principal amount of $1,415,914,725.62; interest rate margin Adjusted Term SOFR plus 2.25%, (effective 2026-05-20).

“On May 20, 2026, Sotera Health Company (the “Company”), Sotera Health Holdings, LLC (“SHH”), certain subsidiaries of the Company, each 2026 Refinancing Term Lender (the “Refinancing Lenders”) and JPMorgan Chase Bank, N.A., as first lien Administrative Agent (the “Administrative Agent”) entered into Amendment No. 7 (the “Amendment”) to the First Lien Credit Agreement dated as of December 13, 2019, by and among the Company, SHH, the Administrative Agent and the lenders and issuing banks party thereto (the “Credit Agreement”).”

Sotera Health Co amended term loan of $1,415,914,725.62 with JPMorgan Chase Bank, N.A., as first lien Administrative Agent at Adjusted Term SOFR plus 2.25% maturing May 30, 2031.

“Among other changes, the Amendment provides that the Refinancing Lenders will provide term loans (the “Repriced Term Loans”) to SHH in an aggregate principal amount of $1,415,914,725.62. The Amendment reduces the interest rate spread by 0.25% across term loans under the facility. The Repriced Term Loans shall have an applicable interest rate margin equal to”

Sotera Health Co reported the quarter ended March 31, 2026 results: net income net income of $27 million, EPS $0.09 per diluted share. Guidance reaffirmed.

“Q1 2026 net income of $27 million or $0.09 per diluted share, compared to a net loss of $13 million or $0.05 per diluted share in Q1 2025 • Q1 2026 Adjusted EBITDA (1) increased 10.5%, or 6.9% on a constant currency basis • Q1 2026 Adjusted EPS (1) of $0.18 , an increase of 29% per diluted share • Company reaffirms full-year 2026 outlook of 5.0% - 6.5% net revenues growth and 5.5% - 7.0% Adjusted EBITDA growth, both on a constant currency basis”

Alton Shader was appointed as Class II director at Sotera Health Co.

“appointed Alton Shader to serve as Chief Executive Officer of the Company ("CEO") and a Class II director of the Board”

Alton Shader was appointed as Chief Executive Officer at Sotera Health Co.

“the Board, at the recommendation of the Nominating and Corporate Governance Committee, appointed Alton Shader to serve as Chief Executive Officer of the Company ("CEO") and a Class II director of the Board, effective as of May 26, 2026”

Michael B. Petras, Jr. was appointed as Executive Chairman of the Board at Sotera Health Co.

“the Board appointed Mr. Petras to serve as Executive Chairman of the Board ("Executive Chairman"), as of the Effective Date.”

Sotera Health Co amended term loan of $1,423,029,875 with JPMorgan Chase Bank, N.A. at Adjusted Term SOFR plus 2.50% maturing May 30, 2031.

“the Amendment provides that the Refinancing Lenders will provide term loans (the “Repriced Term Loans”) to SHH in an aggregate principal amount of $1,423,029,875”

David A. Donnini resigned as Director at Sotera Health Co.

“On September 6, 2024, David A. Donnini, one of GTCR’s designees, notified the Company that, consistent with this decrease, he wished to resign as a director.”

Christopher A. Simon was appointed as Class III director at Sotera Health Co.

“On July 31, 2024, the Board of Directors (the “Board”) of Sotera Health Company (the “Company”) increased the size of the Board from eleven directors to twelve directors and appointed Christopher A. Simon as a Class III director of the Board, effective August 1, 2024.”

Sotera Health Co reported three months ended March 31, 2024 results: revenue $248 million, net income $6 million, or $0.02 per diluted share, EPS $0.02 per diluted share. Guidance reaffirmed.

“incorporated by specific reference in such filing. --- EX-99.1 (EX-99.1) --- Sotera Health Reports First-Quarter 2024 Results • Q1 2024 net revenues increased 12.5% to $248 million, compared to Q1 2023 • Q1 2024 net income of $6 million or $0.02 per diluted share, comp ared to net income of $3 million or $0.01 per diluted share in Q1 2023 • Q1 2024 Adjusted”

Sotera Health Co reported the three months ended March 31, 2024 results: revenue $248 million, net income $6 million, EPS $0.02 per diluted share. Guidance reaffirmed.

“First-quarter 2024 net revenues increased 12.5% to $248 million, compared to $221 million in the first-quarter 2023.”

Sotera Health Co amended Amendment No. 3 with JPMorgan Chase Bank, N.A., as First Lien Administrative Agent and the lenders and issuing banks party thereto (effective 2024-03-01).

“On March 1, 2024, Sotera Health Company (the “Company”) and Sotera Health Holdings, LLC (“SHH”) entered into Amendment No. 3 (the “Amendment”) to the First Lien Credit Agreement dated as of December 13, 2019 by and among the Company, SHH, certain subsidiaries of the Company, JPMorgan Chase Bank, N.A., as First Lien Administrative Agent and the lenders and issuing banks party thereto (the “Credit Agreement”).”

Sotera Health Co updated its FY 2024 guidance (initiated).

“Full-year 2024 outlook of 4.0% - 6.0% growth for Net Revenues and Adjusted EBITDA”

Sotera Health Co reported full year 2023 results: revenue between $1.040 billion and $1.050 billion. Guidance reaffirmed.

“We expect full-year revenues to finish between $1.040 billion and $1.050 billion.”

Karen A. Flynn was appointed as director at Sotera Health Co.

“On November 13, 2023, the Board of Directors (the “Board”) of Sotera Health Company (the “Company”) increased the size of the Board from ten to eleven and appointed Karen A. Flynn to serve as a director of the Company effective November 13, 2023.”

Sotera Health Co reported Q3 2023 results: revenue net revenues of $263 million, net income net loss of $14 million, EPS $0.21 Adjusted EPS. Guidance reaffirmed.

“Sotera Health Reports Third-Quarter and Year-to-Date 2023 Results • Q3 2023 net revenues of $263 million increased 6%, compared to Q3 2022 • Q3 2023 net loss of $14 million or $0.05 per diluted share, compared to net income of $25 million or $0.09 per diluted share in Q3 2022 • Q3 2023 Adjusted EBITDA of $134 million increased 7%, compared to Q3 2022 • Q3 2023 Adjusted EPS of $0.21 decreased $0.02 per diluted share, compared to Q3 2022 driven by higher interest expense • Company reaffirms 2023 outlook, anticipates results at the lower end of the range”

Sotera Health Co reported the quarter ended June 30, 2023 results: revenue $255 million, net income $24 million or $0.08 per diluted share, EPS $0.08 per diluted share. Guidance reaffirmed.

“incorporated by specific reference in such filing. --- EX-99.1 (EX-99.1) --- Sotera Health Reports Second-Quarter and First-Half 2023 Results • Q2 2023 net revenues of $255 million decreased 4%, compared to Q2 2022, primarily driven by expected Nordion Cobalt-60 harvest schedule timing • Q2 2023 net income of $24 million or $0.08 per diluted share, compared”

Michael F. Biehl departed as Interim Chief Financial Officer at Sotera Health Co.

“Mr. Lyons, age 46, who succeeds Michael F. Biehl as the Company's Interim CFO”

Jonathan M. Lyons was appointed as Senior Vice President and Chief Financial Officer at Sotera Health Co.

“On June 26, 2023, Sotera Health Company (the "Company") announced the appointment of Jonathan M. Lyons as Senior Vice President and Chief Financial Officer ("CFO") of the Company, effective June 26, 2023.”

Sotera Health Co amended Amendment with JPMorgan Chase Bank, N.A., as First Lien Administrative Agent (effective 2023-06-22).

“On June 22, 2023, Sotera Health Company (the “Company”) and Sotera Health Holdings, LLC (“SHH”) entered into an amendment (the “Amendment”) to the First Lien Credit Agreement, dated as of December 13, 2019, by and among the Company, SHH, certain subsidiaries of the Company, JPMorgan Chase Bank, N.A., as First Lien Administrative Agent and the lenders and issuing banks party thereto (the “Credit Agreement”).”

Sotera Health Co shareholders approved Ratification of appointment of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2023. at the 2023-05-25 meeting.

“For Against Abstain 269,320,023 504,464 101,038”

Sotera Health Co shareholders approved Advisory approval of named executive officer compensation. at the 2023-05-25 meeting.

“For Against Abstain Broker Non-Vote 229,154,947 38,382,040 112,899 2,275,639”

Sotera Health Co shareholders approved Election of three Class III directors to serve a three-year term until the 2026 annual meeting. at the 2023-05-25 meeting.

“Nominee For Against Abstain Broker Non-Vote Sean L. Cunningham 241,825,403 25,714,700 109,783 2,275,639 Robert B. Knauss 244,567,719 22,972,035 110,132 2,275,639 Vincent K. Petrella 264,410,491 3,136,356 103,039 2,275,639”

Sotera Health Co reported the quarter ended March 31, 2023 results: revenue $221 million, net income $3 million, EPS $0.01 per diluted share. Guidance reaffirmed.

“First-quarter 2023 net revenues decreased 6.8% to $221 million, compared with $237 million in the first-quarter 2022. Net revenues decreased 5.3% on a constant currency basis. Net income (“net income”) was $3 million, or $0.01 per diluted share, compared with net income of $31 million, or $0.11 per diluted share in the first-quarter 2022.”

Sotera Health Co amended Incremental Facility Amendment No. 2 with JPMorgan Chase Bank, N.A., as First Lien Administrative Agent and the lenders and issuing banks party thereto valued at $423,750,000 (effective 2023-03-21).

“On March 21, 2023, Sotera Health Company (the “Company”) and Sotera Health Holdings, LLC (“SHH”) entered into Incremental Facility Amendment No. 2 (the “Amendment”) to the First Lien Credit Agreement dated as of December 13, 2019 by and among the Company, SHH, certain subsidiaries of the Company, JPMorgan Chase Bank, N.A., as First Lien Administrative Agent and the lenders and issuing banks party thereto (the “Credit Agreement”).”

Sotera Health Co updated its Full-year 2023 guidance (initiated).

“Full-year 2023 outlook Net Revenues and Adjusted EBITDA growth of 5% to 9%”

Sotera Health Co incurred term loan of $500,000,000 with JPMorgan Chase Bank, N.A., as First Lien Administrative Agent at Term SOFR (floor 0.50%) + 3.75% or Base Rate + 2.75% maturing December 13, 2026.

“The Credit Agreement provides for, among other things, a new Term Loan B facility in an aggregate principal amount of $500,000,000 (the “Term Facility” and the loans thereunder, the “Term Loans”).”

Sotera Health Co entered into First Lien Credit Agreement with JPMorgan Chase Bank, N.A. (as First Lien Administrative Agent) and the lenders party thereto valued at $500,000,000 (effective 2023-02-23).

“On February 23, 2023, Sotera Health Company (the “Company”) and Sotera Health Holdings, LLC, as the Borrower (“SHH”) entered into the First Lien Credit Agreement dated as of February 23, 2023, by and among the Company, SHH, JPMorgan Chase Bank, N.A., as First Lien Administrative Agent (the “Administrative Agent”) and the lenders party thereto (the “Credit Agreement”).”

Sotera Health Co reported the year ended December 31, 2022 results: revenue $995 million to $1.005 billion, net income $226 million to $236 million. Guidance reaffirmed.

“The Company is reaffirming its expectation that 2022 full-year net revenues will be within the previously announced guidance range of $995 million to $1.005 billion. The Company also is announcing that the 2022 full-year net loss is expected to be in a range of $226 million to $236 million”

Sotera Health Co entered into Term Sheets with Plaintiffs' Executive Committee (PEC) representing Eligible Claimants valued at $408 million (effective 2023-01-09).

“On January 9, 2023, two subsidiaries of Sotera Health Company (the “Company”), Sotera Health LLC and Sterigenics U.S., LLC (“Sterigenics” and, together with Sotera Health LLC, the “Settling Defendants”), entered into binding term sheets (the “Term Sheets”) with a committee (the “Plaintiffs’ Executive Committee” or “PEC”) of 7 of the 20+ law firms (“Plaintiffs’ Counsel”) representing over 870 claimants”

Sotera Health Co reported FY 2022 results: revenue net revenue growth 7% - 8%.

“Adjusting full-year 2022 net revenue growth outlook to 7% - 8% and Adjusted EBITDA growth to 4% - 6%”

Robert B. Knauss was appointed as Director at Sotera Health Co.

“On October 12, 2022, the Board appointed Robert B. Knauss to serve as a director of the Company, effective October 12, 2022.”

Stephanie M. Geveda resigned as Director at Sotera Health Co.

“On October 7, 2022, Stephanie M. Geveda notified Sotera Health Company (the “Company”) of her resignation as a director of the Company, effective October 7, 2022, in connection with her departure from Warburg Pincus LLC (“Warburg Pincus”).”

Matthew Klaben was appointed as Interim Senior Vice President, General Counsel and Secretary at Sotera Health Co.

“Effective October 1, 2022, Mr. Matthew Klaben, Deputy General Counsel, will serve as Interim Senior Vice President, General Counsel and Secretary of the Company.”

Terrence Hammons resigned as Senior Vice President, General Counsel and Secretary at Sotera Health Co.

“accepted Terrence Hammons’ resignation from his position as Senior Vice President, General Counsel and Secretary of the Company for personal reasons.”

Michael F. Biehl was appointed as Interim Chief Financial Officer at Sotera Health Co.

“Effective July 20, 2022, Mr. Michael F. Biehl was appointed Interim Chief Financial Officer of the Company and will serve as the Company’s principal accounting officer.”

Scott J. Leffler resigned as Chief Financial Officer at Sotera Health Co.

“Mr. Leffler will now depart from the Company on July 20, 2022.”

Scott J. Leffler resigned as Chief Financial Officer at Sotera Health Co.

“On May 16, 2022, Scott J. Leffler, who is currently Chief Financial Officer and Treasurer, informed Sotera Health Company (the “Company”) of his decision to resign from his position at the Company to pursue other opportunities and to relocate to Florida for personal reasons.”